EyePoint Pharmaceuticals, Inc.
General ticker "EYPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
EyePoint Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -12.4%.
Estimated limits based on current volatility of 1.4%: low 4.18$, high 4.57$
Factors to consider:
- Total employees count: 165 (+36.4%) as of 2024
- US accounted for 97.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Market acceptance, Market competition
- Current price 47.9% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.20$, 26.29$]
- 2026-12-31 to 2027-12-31 estimated range: [6.26$, 18.76$]
Financial Metrics affecting the EYPT estimates:
- Negative: with PPE of -5.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.91 <= 0.28
- Positive: Investing cash flow per share per price, % of 5.11 > -0.64
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term EYPT quotes
Long-term EYPT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $46.02MM | $43.27MM | $31.37MM |
| Operating Expenses | $121.08MM | $189.13MM | $274.81MM |
| Operating Income | $-75.07MM | $-145.85MM | $-243.43MM |
| Non-Operating Income | $4.36MM | $15.07MM | $11.75MM |
| Interest Expense | $1.25MM | $0.01MM | $0.03MM |
| R&D Expense | $64.66MM | $132.93MM | $221.04MM |
| Income(Loss) | $-70.71MM | $-130.78MM | $-231.68MM |
| Taxes | $0.08MM | $0.09MM | $0.28MM |
| Net Income(Loss)* | $-70.80MM | $-130.87MM | $-231.96MM |
| Stockholders Equity | $266.32MM | $336.50MM | $306.11MM |
| Inventory | $3.91MM | $2.31MM | $1.81MM |
| Assets | $355.18MM | $418.46MM | $364.00MM |
| Operating Cash Flow | $1.88MM | $-126.23MM | $-240.11MM |
| Capital expenditure | $3.48MM | $4.05MM | $3.28MM |
| Investing Cash Flow | $-3.31MM | $-219.35MM | $68.58MM |
| Financing Cash Flow | $187.07MM | $164.02MM | $173.65MM |
| Earnings Per Share** | $-1.82 | $-2.32 | $-3.17 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.